IFNB1 and myeloid sarcoma: Because increased Vδ1−Vδ2−Vγ9− cells were associated with a better outcome, especially in MS patients fulfilling NEDA under IFN-β treatment, Vδ1−Vδ2−Vγ9− cells might be a target for the therapeutic immunomodulation of MS.